< Terug naar vorige pagina
Onderzoeker
Mona Bové
- Trefwoorden:antibioticaresistentie
- Disciplines:Bacteriologie
Affiliaties
- Vakgroep Farmaceutische Analyse (Departement)
Lid
Vanaf18 sep 2018 → 30 sep 2022
Projecten
1 - 1 of 1
- Studie van de evolutionaire robuustheid van antimicrobiële combinatietherapie voor de behandeling van biofilm-gerelateerde infecties door Gram-negatieve bacteriënVanaf1 okt 2018 → 30 sep 2022Financiering: BOF - Nieuwe Onderzoeksinitiatieven
Publicaties
1 - 8 van 8
- Biofilm antimicrobial susceptibility through an experimental evolutionary lens(2022)
Auteurs: Tom Coenye, Mona Bové, Thomas Bjarnsholt
- Phenotypic characterization and heterogeneity among modern clinical isolates of Acinetobacter baumannii(2022)
Auteurs: Adam Valcek, Chantal Philippe, Clemence Whiteway, Etienne Robino, Kristina Nesporova, Mona Bové, Tim De Pooter, Wouter De Coster, Mojca Strazisar, Charles Van der Henst
- Assessing the evolutionary robustness of anti-biofilm combination therapy(2022)
Auteurs: Mona Bové
- The quorum-sensing inhibitor furanone C-30 rapidly loses its tobramycin-potentiating activity against Pseudomonas aeruginosa biofilms during experimental evolution(2021)
Auteurs: Mona Bové, Xuerui Bao, Andrea Sass, Aurélie Crabbé
- Various Evolutionary Trajectories Lead to Loss of the Tobramycin-Potentiating Activity of the Quorum-Sensing Inhibitor Baicalin Hydrate in Burkholderia cenocepacia Biofilms(2019)
Auteurs: Andrea Sass, Lisa Slachmuylders, Heleen Van Acker, Ian Vandenbussche, Lisa Ostyn, Mona Bové, Aurélie Crabbé, Laurent R Chiarelli, Silvia Buroni, Filip Van Nieuwerburgh, et al.
- The anti-virulence activity of the non- mevalonate pathway inhibitor FR900098 towards Burkholderia cenocepacia is maintained during experimental evolution
Auteurs: Mona Bové
- Organic acids and their salts potentiate the activity of selected antibiotics against Pseudomonas aeruginosa biofilms grown in a synthetic cystic fibrosis sputum medium
Auteurs: Xuerui Bao, Mona Bové
- Adaptation of Pseudomonas aeruginosa biofilms to tobramycin and the quorum sensing inhibitor C-30 during experimental evolution requires multiple genotypic and phenotypic changes
Auteurs: Mona Bové, Mette Kolpen, Mads Lichtenberg, Thomas Bjarnsholt